Biotech Values

[kris_kade]

Dew,

Per recent CC, RVNC management indicated "With regard to our SAKURA glabellar lines program, we plan to release Phase III pivotal trial results covering safety before we composite primary endpoint and the secondary endpoints including duration".

Does this mean safety and efficacy/duration will be reported in two different PR's ? Not sure why Revance is choosing to report in this manner. T.I.A